Literature DB >> 31016326

Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice?

Joachim Neumann1, Benedikt Käufler1, Ulrich Gergs2.   

Abstract

Serotonin (5-hydroxy-tryptamine, 5-HT) exerted concentration-dependent positive inotropic effects or positive chronotropic effects in transgenic (TG) mice which overexpress the human 5-HT4a receptor in the heart but not in littermate wild-type (WT) mice. These positive inotropic effects and positive chronotropic effects are thought to be mediated by cyclic adenosine 3',5'-monophosphate (cAMP) in TG cardiomyocytes. To determine whether these effects are antagonized by endogenous phosphodiesterases (PDEs), the inotropic and chronotropic effects of 5-HT were tested in the additional presence of the PDE inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine hydrochloride (EHNA) (1 μM, a PDE2 inhibitor) or cilostamide (1 μM, a PDE3 inhibitor), rolipram (0.1 μM and 1 μM, a PDE4 inhibitor), and their combinations. For comparison, 3-isobutyl-1-methylxanthine (IBMX), an unspecific PDE inhibitor, was investigated. The use of 10 μM IBMX, the combination of rolipram (1 μM) and EHNA (1 μM), and the combination of rolipram (0.1 μM) and cilostamide (1 μM) each increased the potency of 5-HT to elevate the force of contraction in TG mice, but not the potency of 5-HT to increase the beating rate in TG mice. This indicates that PDE4 and PDE2 regulate the inotropic but not the chronotropic effects of 5-HT in TG mice. In contrast, cilostamide (1 μM) alone, EHNA (1 μM) alone, or in combination decreased the potency of 5-HT to increase force of contraction in TG mice. In summary, our present data suggest that the positive chronotropic effect of 5-HT in TG mice does not involve PDE activities, whereas the positive inotropic effect of 5-HT and the basal force in TG mice are diminished by endogenous activity of PDE4. Phosphorylation of PDE4, when PDE2 or PDE3 is inhibited, might enhance the activity of PDE4.

Entities:  

Keywords:  5-HT4 receptor; Chronotropy; Inotropy; Phosphodiesterase; Serotonin; Transgenic mice

Year:  2019        PMID: 31016326     DOI: 10.1007/s00210-019-01653-y

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  42 in total

1.  Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior.

Authors:  Joris H De Maeyer; Nicolaas H Prins; Jan A J Schuurkes; Romain A Lefebvre
Journal:  J Pharmacol Exp Ther       Date:  2006-02-24       Impact factor: 4.030

Review 2.  Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.

Authors:  Grace E Kim; David A Kass
Journal:  Handb Exp Pharmacol       Date:  2017

3.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 4.  Regulation of basal and reserve cardiac pacemaker function by interactions of cAMP-mediated PKA-dependent Ca2+ cycling with surface membrane channels.

Authors:  Tatiana M Vinogradova; Edward G Lakatta
Journal:  J Mol Cell Cardiol       Date:  2009-06-30       Impact factor: 5.000

5.  Age-dependent biochemical and contractile properties in atrium of transgenic mice overexpressing junctin.

Authors:  Uwe Kirchhefer; Hideo A Baba; Gabriela Hanske; Larry R Jones; Paulus Kirchhof; Wilhelm Schmitz; Joachim Neumann
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-06-17       Impact factor: 4.733

6.  5-HT4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles.

Authors:  F Afzal; K W Andressen; H K Mørk; J M Aronsen; I Sjaastad; C P Dahl; T Skomedal; F O Levy; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2008-09-01       Impact factor: 8.739

7.  Sensitization of human atrial 5-HT4 receptors by chronic beta-blocker treatment.

Authors:  L Sanders; J A Lynham; B Bond; F del Monte; S E Harding; A J Kaumann
Journal:  Circulation       Date:  1995-11-01       Impact factor: 29.690

8.  Human 5-HT₄receptor stimulation in atria of transgenic mice.

Authors:  Ulrich Gergs; Anne Böckler; Henning Ebelt; Steffen Hauptmann; Nicolas Keller; Volker Otto; Klaus Pönicke; Wilhelm Schmitz; Joachim Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-01-11       Impact factor: 3.000

9.  Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors.

Authors:  A Galindo-Tovar; A J Kaumann
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

10.  Conserved expression and functions of PDE4 in rodent and human heart.

Authors:  Wito Richter; Moses Xie; Colleen Scheitrum; Judith Krall; Matthew A Movsesian; Marco Conti
Journal:  Basic Res Cardiol       Date:  2010-12-16       Impact factor: 17.165

View more
  1 in total

1.  Phosphodiesterases 2, 3 and 4 can decrease cardiac effects of H2-histamine-receptor activation in isolated atria of transgenic mice.

Authors:  Joachim Neumann; Rafaela Voss; Ulrich Laufs; Christian Werner; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-02-12       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.